X

Drug Profile

Anti-CD5 monoclonal antibody OX19

Alternative Names: Monoclonal antibody OX19; OX19

Latest Information Update: 06 Aug 1998

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Class Monoclonal antibodies
Mechanism of Action CD5 antigen inhibitors; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Transplant rejection

Most Recent Events

06 Aug 1998 No-Development-Reported for Transplant rejection in Japan (Unknown route)
19 Jul 1996 Monoclonal antibody OX19 is now called Anti-CD5 monoclonal antibody OX19
08 Sep 1995 Preclinical development for Transplant rejection in Japan (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com